Total Funding
61
50
Total FundingSeries C raised
Growth Score
-3 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
78890
Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformatics
Ryu Ogawa: CEO & Co-founder- Natsumi Negishi: The Head of Corporate DevelopmentPast Role: STRIVE, Partner
About the Company
Molcure is antibody and Peptide drug-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of patients by developing and providing more effective therapeutics and supportive care products. Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the
partner of choice for therapeutic antibody discovery. At Molcure they combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies. Their technology is validated through a number of partnerships. They are seeking new partnership opportunities.
